Clinical trial
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With…
NCT00446433 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00446433 |
|---|---|
| Title | A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 90 |
| Start date | Mar 1, 2002 |
| Completion | Dec 1, 2003 |
| First posted | Mar 12, 2007 |
| Last update posted | Dec 1, 2016 |
| Countries | France, Israel, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: